Navigation Links
Common bowel problem linked to chili pepper pain receptor
Date:6/10/2008

People with irritable bowel syndrome have a higher than usual number of chilli pepper pain receptors, according to a new study published tomorrow (Wednesday 11 June).

The research, published in the journal Gut, could lead to new therapies for the estimated one in five UK adults who have irritable bowel syndrome (IBS), a painful condition which is poorly understood. Symptoms of IBS include abdominal pain, bloating, and bowel problems such as constipation or diarrhoea.

The new research shows that people with IBS have higher than usual levels of nerve fibres expressing the pain receptor TRPV1, responsible for causing a burning sensation when people eat chilli peppers. The study's authors, from Imperial College London, hope that doctors could treat the pain that people with IBS experience by targeting and blocking this receptor.

People with severe pain from IBS are currently treated with opiates, which can have serious side-effects. Painkillers such as paracetamol and ibuprofen tend to offer little relief. New painkillers to target TRPV1 are currently being developed by pharmaceutical companies and the new findings suggest that such drugs could tackle some of the symptoms of IBS.

The researchers believe their findings may explain why some people's IBS symptoms worsen after eating spicy food. They also suggest that the presence of more nerve fibres expressing the TRPV1 pain receptors might mean that people with IBS are more susceptible to pain.

Professor Subrata Ghosh, one of the authors of the study from the Division of Medicine at Imperial College London, said: "IBS can seriously affect people's quality of life and our new study could explain some of its symptoms. At the moment patients don't have a lot of options for managing their condition and the treatments we can offer can give disappointing results. We hope that our findings will lead to better treatments to help people with IBS."

Professor Praveen Anand, an author of the study from the Division of Neuroscience and Mental Health at Imperial College, added: "Up to 50 pharmaceutical and biotech companies world-wide are developing drugs that block the chilli pepper receptor TRPV1, and our published studies on this receptor in a number of chronic pain and hypersensitivity conditions provide hope for millions of suffering patients."

The researchers reached their conclusions after comparing biopsies of colon tissue taken from 23 patients with IBS and 22 controls, recruited from the Gastroenterology clinics and the endoscopy department at Imperial College Healthcare NHS Trust. The biopsies were studied in the Division of Neuroscience and Mental Health at Imperial College London.


'/>"/>

Contact: Laura Gallagher
L.Gallagher@imperial.ac.uk
44-020-759-46702
Imperial College London
Source:Eurekalert

Related medicine news :

1. Finding the source: Cells that initiate a common infant tumor identified
2. Inflammation, depression and antidepressant response: Common mechanisms
3. American Heart Association Survey Reveals Americans Lack Confidence in Lifesaving Skills for Common Cardiac Emergency
4. Common Genetic Variant Tied to Lung Cancer Risk
5. A common denominator of inflammations and fatty liver
6. Mayo Clinic researchers find common gene disorder doubles risk of lung cancer, even among nonsmokers
7. PA ABC Will Benefit Commonwealths Small Businesses, DCED Secretary Says
8. Incidental adrenal masses commonly seen on CT are usually benign; no follow-up needed
9. Smallpox Drug May Protect Against Common Cold
10. Womens Health Crisis: GI Problems Common in Women
11. Study finds 21st birthday binge drinking extremely common; can pose serious health hazards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... cold therapy products, announced today the introduction of an innovative new design of the ... multipurpose pad so you get maximum comfort while controlling your pain while using cold ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will join ... International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey Dome, ... at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division of ...
(Date:10/12/2017)... ... 2017 , ... Health Literacy Innovations (HLI), creator of the ... the Cancer Patient Education Network (CPEN), an independent professional organization that shares best ... alliance. , As CPEN’s strategic partner, HLI will help support CPEN members ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical ... innovative solutions for injectable drug administration, today shared the ... ID Adapter for improving the intradermal administration of polio ... Skin Vaccination Summit in May 2017 by Dr. ... Polio Department, World Health Organization (WHO), and recently published ...
(Date:10/4/2017)... 2017  According to the Centers for Disease Control and Prevention (CDC), ... PhysicianOne Urgent Care is helping communities across Massachusetts , ... by offering no-cost* flu shots through the end of the month. ... insurance regulations. ... get a flu shot is by the end of October, according to ...
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, the ... by Walgreens and pharmacy benefit manager Prime Therapeutics LLC ... brand, which included the unveiling of new signage at ... as well as at a few other company-owned facilities ... brand to patients, some of whom will begin to ...
Breaking Medicine Technology: